Multiple Myeloma Clinical Trial
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
Summary
The purpose of this study is to test 89Zr-DFO-daratumumab, a new imaging agent, to demonstrate its safety and ability to take pictures of the myeloma.
Eligibility Criteria
Inclusion Criteria:
Age 21 years or greater
Histologically/Immunohistochemistry confirmed CD38-positive multiple myeloma
At least one tumor lesion on CT, MRI, or FDG PET/CT within 60 days of protocol enrollment
ECOG performance status 0 to 2
For Phase II patients only: plan for initiation of standard-of-care daratumumab/lenalidomide therapy.
Exclusion Criteria:
Life expectancy < 3 months
Pregnancy or lactation
Patients who cannot undergo PET/CT scanning because of weight limits. PET/CT scanners may not be able to function with patients over 450 pounds.
History of anaphylactic reaction to humanized or human antibodies or a Grade 3 or 4 administration reaction during a daratumumab administration.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
New York New York, 10065, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.